The paediatric MATCH screening trial intended to study Tazemetostat in patients with NHL, histiocytic disorders or solid tumors that harbour an EZH2, SMARCB1 or SMARCA4 mutation (NCT03155620), however this arm of the trial has been put on partial hold by the FDA (NCT03213665). This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.